Phases précoces tumeurs solides XL 184_021 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Paris
Phases précoces tumeurs solides INCB 86550-102 A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides BGB-A317-A3055-101 A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides MCLA-158-CL01 Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides DF1001-001 A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications Paris EMANUELA ROMANO
Phases précoces tumeurs solides GCT1047-01 First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides LCB-1801-001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF NI-1801, A BISPECIFIC MESOTHELIN x CD47 ENGAGING ANTIBODY,IN PATIENTS WITH MESOTHELIN EXPRESSING SOLID CANCERS. Paris EMANUELA ROMANO
Phases précoces tumeurs solides GO30103 (TIGIT) A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors. Paris EMANUELA ROMANO
Phases précoces tumeurs solides CLEVER-PEPTIDE (IC 2018-06) Open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides EMBER (J2J-MC-JZLA) EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers. Paris JEAN-YVES PIERGA